Nicolas Ferreyros discusses the Community Oncology Alliance’s position statements on biomarker testing and physician autonomy.

A phase 1/2 trial of CRISPR-engineered eTIL therapy KSQ-004EX for advanced solid tumors has dosed its first patient.

In a live virtual event, Attaya Suvannasankha, MD, discussed the MajesTEC-1 trial of teclistamab and approaches to mitigation ...

During a live event, Matthew Galsky, MD discussed neoadjuvant and adjuvant options for a patient case including nivolumab or dose-dense MVAC.

The DecisionDx-Melanoma test accurately identifies low sentinel lymph node risk in melanoma, according to the DECIDE study.

Nicolas Ferreyros discussed central ideas from the Community Oncology Alliance to optimize cancer care in community oncology ...

Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular carcinoma ...

A real-world study has reinforced the efficacy and safety of teclistamab in heavily pretreated patients with ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Experts discuss how disease progression impacts patients with diffuse large B-cell lymphoma (DLBCL) and strategies for managing progressive disease based on first-line therapy selection, incorporating ...

Video content above is prompted by the following: Please discuss how long-term data influence your current and future approach to first-line DLBCL treatment. • How do these outcomes shape your view ...

Video content above is prompted by the following: Please discuss the decision-making factors and real-world challenges that shape treatment selection in DLBCL patient care. • How do you weigh efficacy ...